Rubrofusarin gentiobioside
Based on 1 Customer Validation
Rubrofusarin gentiobioside (Rrubrofusarin-6-β-gentiobioside) is an orally active weak inhibitor of PTP1B and MAO-A (IC50 >100 μM), and its glycosylation modification results in lower biological activity than its aglycone Rubrofusarin (HY-130307). Rubrofusarin gentiobioside promotes AMPK phosphorylation in an LKB1-independent manner and inhibits the mTOR signaling pathway, thereby downregulating the expressions of PPARγ, C/EBPα, as well as FAS, LPL and aP2. Rubrofusarin gentiobioside inhibits lipid accumulation, reduces body weight and epididymal white adipose tissue volume, improves fatty liver, and shows no cytotoxicity to hepatocytes. Rubrofusarin gentiobioside is widely used in obesity-related studies.
For research use only. We do not sell to patients.
- Purity: 99.07%
- CAS No.: 24577-90-0
- Formula: C27H32O15
- Molecular Weight:596.53
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Kinase Inhibitor Library
HY-L009
-
Metabolism/Protease Compound Library
HY-L012
-
Neuronal Signaling Compound Library
HY-L013
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Natural Product Library
HY-L021
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Glycoside Compound Library
HY-L042
-
Oxygen Sensing Compound Library
HY-L045
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Phosphatase Inhibitor Library
HY-L081
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Mitochondria-Targeted Compound Library
HY-L089
-
Transcription Factor-Targeted Library
HY-L090
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Food-Sourced Compound Library
HY-L094
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
Plant-Sourced Natural Product Library
HY-L115
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Nuclear Receptor Compound Library
HY-L126
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Anti-Brain Cancer Compound Library
HY-L188
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
All AMPK Isoforms
More
Biological Activity
|
MAO-A |
PPAR-γ |
Rubrofusarin gentiobioside (200, 400 μM; 48 h) is non-cytotoxic to 3T3-L1 murine pre-adipocytes[1].
Rubrofusarin gentiobioside (50, 100, 200 μM) activates AMPKα in an LKB1-independent manner, suppresses mTOR phosphorylation, and does not regulate the PI3K/AKT pathway in differentiated 3T3-L1 murine pre-adipocytes at concentrations of 50, 100, and 200 μM[1].
Rubrofusarin gentiobioside (400 μM; 48 h) is non-cytotoxic to human adipose mesenchymal stem cells at concentrations up to 400 μM when incubated for 48 h[1].
Rubrofusarin gentiobioside (25-100 μM) is non-toxic to HepG2 human hepatocarcinoma cells at concentrations up to 100 μM[2].
Rubrofusarin gentiobioside has limited druglike properties per Lipinski’s rule and poor predicted ADME characteristics including low intestinal absorption and blood-brain barrier penetration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:3T3-L1 murine pre-adipocytes
-
Concentration:0, 50, 100, 200, 400 μM
-
Incubation Time:48 h
-
Result:Did not exert cytotoxicity at concentrations up to 200 μM.
Caused a statistically significant reduction in cell viability (p < 0.05) relative to the untreated control at 400 μM.
-
Cell Line:human adipose mesenchymal stem cells (hAMSCs)
-
Concentration:0, 50, 100, 200, 400 μM
-
Incubation Time:48 h
-
Result:Did not exhibit cytotoxicity at any tested concentration up to 400 μM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 J mice with Obesity (male, 4 weeks old, 16-18 g, HFD-induced obesity)[1]
-
Dosage:50 mg/kg/day; 100 mg/kg/day
-
Administration:p.o.; daily; 10 weeks
-
Result:Reduced weight gain by 19.7% (50 mg/kg/day) and 30.9% (100 mg/kg/day) relative to HFD-only group.
Reduced epididymal white adipose tissue weight relative to HFD-only group.
Prevented liver weight increase relative to HFD-only group.
Decreased serum total cholesterol, LDL-cholesterol, free fatty acid, glucose, and leptin levels, and increased adiponectin levels relative to HFD-only group.
Reduced adipocyte size to 4079 μM2 (50 mg/kg/day) and 2813 μM2 (100 mg/kg/day) relative to 5944 μM2 in HFD-only group.
Reduced hepatic lipid accumulation relative to HFD-only group.
Decreased protein and mRNA expression of PPARγ and C/EBPα in epididymal white adipose tissue and liver relative to HFD-only group.
Increased phosphorylation of AMPK and decreased phosphorylation of mTOR in epididymal white adipose tissue and liver relative to HFD-only group.
Downregulated mRNA expression of FAS, LPL, and aP2 in epididymal white adipose tissue and liver relative to HFD-only group.
Chemical Information
-
CAS No. 24577-90-0
-
Appearance Solid
-
Molecular Weight 596.53
-
Formula C27H32O15
-
Color Light yellow to yellow
-
SMILES
O[C@H]1[C@H](OC2=CC(OC)=CC3=C2C(O)=C4C(C=C(C)OC4=C3)=O)O[C@H](CO[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)[C@@H](O)[C@@H]1O
-
Synonyms
Rubrofusarin-6-β-gentiobioside
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 100 mg/mL (167.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Han YH, et al. Rubrofusarin-6-β-gentiobioside inhibits lipid accumulation and weight gain by regulating AMPK/mTOR signaling. Phytomedicine. 2019;62:152952. [Content Brief]
[2]. Paudel P, et al. Rubrofusarin as a Dual Protein Tyrosine Phosphate 1B and Human Monoamine Oxidase-A Inhibitor: An in Vitro and in Silico Study. ACS Omega. 2019;4(7):11621-11630. Published 2019 Jul 3. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6764 mL | 8.3818 mL | 16.7636 mL | 41.9090 mL |
| 5 mM | 0.3353 mL | 1.6764 mL | 3.3527 mL | 8.3818 mL | |
| 10 mM | 0.1676 mL | 0.8382 mL | 1.6764 mL | 4.1909 mL | |
| 15 mM | 0.1118 mL | 0.5588 mL | 1.1176 mL | 2.7939 mL | |
| 20 mM | 0.0838 mL | 0.4191 mL | 0.8382 mL | 2.0955 mL | |
| 25 mM | 0.0671 mL | 0.3353 mL | 0.6705 mL | 1.6764 mL | |
| 30 mM | 0.0559 mL | 0.2794 mL | 0.5588 mL | 1.3970 mL | |
| 40 mM | 0.0419 mL | 0.2095 mL | 0.4191 mL | 1.0477 mL | |
| 50 mM | 0.0335 mL | 0.1676 mL | 0.3353 mL | 0.8382 mL | |
| 60 mM | 0.0279 mL | 0.1397 mL | 0.2794 mL | 0.6985 mL | |
| 80 mM | 0.0210 mL | 0.1048 mL | 0.2095 mL | 0.5239 mL | |
| 100 mM | 0.0168 mL | 0.0838 mL | 0.1676 mL | 0.4191 mL |
Powered by Bioz